Saint Therapeutics (ST) is a clinical-stage biotechnology company focused on revolutionizing tissue repair and transforming the billion-dollar scar reduction and chronic wound healing markets. Building upon over 20 years of research into fetal scar-free healing, ST is developing SLI-F06 — a patent-protected, first-in-class peptide drug designed to:

1. Reduce scar formation after surgeries via intradermal injection (Phase 1/2a study completed with 54 patients).

2. Promote healing in diabetic foot ulcers via topical application.